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Abstract
Interleukin-12 (IL-12) can promote tumor regression via activation of multiple lymphocytic and
myelocytic eVectors. Whereas the cytotoxic mechanisms employed by T/NK/NKT cells in
IL-12-mediated tumor kill are well deWned, the antitumor role of macrophage-produced cytotoxic
metabolites has been more controversial. To this end, we investigated the speciWc role of nitric oxide
(NO), a major macrophage eVector molecule, in post-IL-12 tumor regression. Analysis of tumors
following a single intratumoral injection of slow-release IL-12 microspheres showed an IFN�-dependent
sevenfold increase in inducible nitric oxide synthase (iNOS) expression within 48 h. Flow cytometric
analysis of tumor-resident leukocytes and in vivo depletion studies identiWed CD11b+ F4/80+ Gr1lo
macrophages as the primary source of iNOS. Blocking of post-therapy iNOS activity with
N-nitro-L-arginine methyl ester (L-NAME)dramatically enhanced tumor suppression revealing the
inhibitory eVect of NO on IL-12-driven antitumor immunity. Superior tumor regression in mice
receiving combination treatment was associated with enhanced survival and proliferation of activated
tumor-resident CD8+ T-eVector/memory cells (Tem). These Wndings demonstrate that
macrophageproduced NO negatively regulates the antitumor activity of IL-12 via its detrimental eVects
on CD8+ T cells and identify L-NAME as a potent adjuvant in IL-12 therapy of cancer.
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Abstract Interleukin-12 (IL-12) can promote tumor
regression via activation of multiple lymphocytic and myelo-
cytic eVectors. Whereas the cytotoxic mechanisms employed
by T/NK/NKT cells in IL-12-mediated tumor kill are well
deWned, the antitumor role of macrophage-produced cyto-
toxic metabolites has been more controversial. To this end,
we investigated the speciWc role of nitric oxide (NO), a major
macrophage eVector molecule, in post-IL-12 tumor regres-
sion. Analysis of tumors following a single intratumoral
injection of slow-release IL-12 microspheres showed an
IFN-dependent sevenfold increase in inducible nitric oxide
synthase (iNOS) expression within 48 h. Flow cytometric
analysis of tumor-resident leukocytes and in vivo depletion
studies identiWed CD11b+ F4/80+ Gr1lo macrophages as the
primary source of iNOS. Blocking of post-therapy iNOS
activity with N-nitro-L-arginine methyl ester (L-NAME)
dramatically enhanced tumor suppression revealing the
inhibitory eVect of NO on IL-12-driven antitumor immunity.
Superior tumor regression in mice receiving combination
treatment was associated with enhanced survival and prolif-
eration of activated tumor-resident CD8+ T-eVector/memory
cells (Tem). These Wndings demonstrate that macrophage-
produced NO negatively regulates the antitumor activity of
IL-12 via its detrimental eVects on CD8+ T cells and identify
L-NAME as a potent adjuvant in IL-12 therapy of cancer.
Keywords Tumor · Immune therapy · Interleukin-12 · 
iNOS · Nitric oxide · CD8+ T cell
Introduction
IL-12 promotes the eradication of established tumors via
activation of diverse innate and adaptive eVector mecha-
nisms [1]. In addition to direct induction of T, NK, and
NKT cell cytotoxicity, IL-12 also promotes macrophage
activity via T- and NK-cell-produced IFN [1]. Several
studies demonstrated that macrophage activation is critical
to the antitumor eVects of this cytokine [2–5]. SpeciWcally,
intratumoral delivery of IL-12 was shown to induce a rapid
switch in tumor-associated macrophage (TAM) phenotype
from M2 to M1 and release of IL-15, a cytokine that was
found to be essential to T- and NK-cell recruitment, and
tumor kill [5]. The role of direct macrophage cytotoxicity
in post-IL-12 tumor regression on the other hand is less
well deWned [3].
Macrophage eVector function is mediated by several
cytotoxic metabolites including nitric oxide (NO), a
molecule with pleiotropic functions [6–8]. In the tumor
microenvironment, NO can be produced by constitutive
nitric oxide synthase activity (cNOS) in the stroma and
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tumor cells or by iNOS in inWltrating myeloid cells [7,
8]. Under steady-state conditions, tumor-produced NO
can promote growth via its agonistic eVects on angio-
genesis and invasion [9–12]. In contrast, macrophage-
produced NO can suppress tumor growth through its
cytotoxic activity [7]. The detrimental eVects of NO,
however, are not limited to tumor cells and have also
been shown to extend to lymphocytes [13–15].
The exact role of macrophage-produced NO in IL-12-
mediated tumor suppression has been controversial with
both anti- and pro-tumorigenic eVects reported. Whereas
several studies identiWed the IL-12-IFN-iNOS axis as
critical to tumor eradication [2, 4], others showed that
IL-12, when administered as an adjuvant in combination
with an irradiated tumor cell vaccine, can interfere with
T-cell priming in an NO-dependent manner [13]. To this
end, the requirement for this metabolite in IL-12 therapy
of established tumors was examined in a well-character-
ized syngeneic murine tumor model. The results demon-
strate that IL-12-IFN-iNOS axis acts as a negative
regulator of IL-12-driven cytotoxic T-cell (CTL)
responses.
Materials and methods
Mice, tumor cells, and reagents
Six- to 8-week-old wild-type and IFN-deWcient BALB/c
mice (Jackson Laboratories) were used. The BALB/c lung
alveolar carcinoma Line-1 has been described [16]. Recom-
binant murine IL-12 was a gift from Wyeth, Inc.
(Cambridge, MA). Induction and monitoring of tumor
growth and the preparation of microspheres were as
reported previously [17]. BrieXy, mice were injected s.c.
with 1 £ 106 viable tumor cells in 0.1 ml sterile PBS
behind the neck just above the scapula. Tumors were
allowed to reach a size of 200–300 mm3 (9–11 days after
tumor cell injection) and were treated with blank or IL-12
microspheres (4 mg microspheres containing 1 g of
recombinant murine IL-12 in 0.1 ml saline) unless other-
wise noted. For inhibition of iNOS activity, L-NAME was
injected ip (0.2 mg/200 l PBS) daily for 10 days starting
6 h before microsphere treatment.
Preparation of single-cell suspensions and Xow cytometry
Single-cell suspensions were prepared by enzymatic diges-
tion of tumors [17] and were analyzed on a four-color
FACSCalibur Xow cytometer (BD Biosciences). Fluoro-
chrome-conjugated anti-mouse mAbs to Gr-1 (RB6-8C5),
Ly6C (AL-21), CD11b (M1/70), CD8 (53–6.7), iNOS
(6/iNOS/NOS type II), CCR3 (83103), and all isotype controls
were purchased from BD Pharmingen. Anti-Ly6G (1A8)
and anti-F4/80 (BM8) were obtained from BioLegend and
eBioscience, respectively. All other mAbs were described
previously [17]. For intracellular iNOS staining, CytoWx/
Cytoperm Plus kit (BD Pharmingen) was used as per manu-
facturer’s instructions.
Quantitative real-time PCR (qRT-PCR) analysis
Fine needle aspirates (FNA) for qRT-PCR were obtained and
processed as described [18]. The primer sequences were as fol-
lows: -actin, 5-TCACCCACACTGGCCCATCTACGA-
3(forward) and 5 TGGTGAAGCTGTAGCCAC GCT-3
(reverse); iNOS, 5-TGGCCACCTTGTTCAGCTACG-3
(forward) and 5GCCAAG GCCAAACACAGCATAC-3
(reverse); Arginase I, 5-AAGAAAAGGCCGATTCACC
T-3 (forward) and 5-CACCTCCTCTGCTGTCTTCC-3
(reverse); CD8, 5-GCTAC CACAGGAGCCGAAAG-3
(forward) and 5-TGGGCTTGCCTTCCTGTCT-3 (reverse).
QuantiWcation of mRNA was performed using the comparative
threshold cycle (Ct) method [18].
In vivo CD8 T-cell and macrophage depletions
Anti-mouse CD8 mAb 53.6.72 (BioXcell) was used to
deplete CD8 T cells via i.p. injection of 200 ug of anti-CD8
on days 1 and 5 [19]. For macrophage depletions, clodro-
nate-containing liposomes and empty control liposomes
were administered as described [20]. BrieXy, liposomes
were diluted in PBS and injected i.p. at a dose of 1.5 mg
clodronate per 20 g body weight on day 2. A second dose of
depleting and control liposome preparations (0.1 mg) was
administered intratumorally on day 0. Mice were sacriWced,
and single-cell suspensions were prepared on day 2.
BrdU labeling and apoptosis assay
BrdU labeling of CD8 T cells was performed as described
[21]. BrieXy, animals were injected with BrdU in 0.1 ml of
sterile PBS (100 mg/kg body weight) i.p. 4 h before sacri-
Wce, and immunostaining for BrdU was performed using
the BD Pharmingen BrdU Xow kit as per the supplier’s
instructions. For detection of apoptosis, cells were Wrst
stained for the CD8 antigen and then with anti-Annexin
V-allophycocyanin (APC) Ab according to the manufac-
turer’s protocol (Annexin V apoptosis detection kit; BD
Pharmingen) [21].
Statistical analysis
Student’s t-test was utilized to determine the signiWcance of
the diVerences between groups, and P · 0.05 was consid-
ered signiWcant.
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Results
IL-12 treatment induces iNOS expression 
in tumor-associated macrophages (TAM)
To determine whether sustained release of IL-12 to the
tumor microenvironment upregulated iNOS expression,
intratumoral mRNA levels were monitored by qRT-PCR.
Tissue samples were obtained from tumors by Wne needle
aspiration (FNA) before therapy and at diVerent time points
following treatment, and iNOS mRNA was quantiWed. The
data shown in Fig. 1a demonstrate that iNOS was induced
within 24 h of treatment, peaked on day 2 (sevenfold
increase over pre-treatment), and declined thereafter.
Importantly, the upregulation of iNOS was accompanied by
a concomitant decrease (up to fourfold) in arginase,
suggesting a switch in TAM phenotype [22]. In contrast,
control-treated mice did not show signiWcant changes in
either marker (data not shown).
Whereas the above data demonstrated a dramatic
increase in intratumoral iNOS expression following IL-12
treatment, the cellular source of iNOS was not identiWed.
This enzyme is primarily expressed by the heterogeneous
CD11b+ Gr-1+ double-positive (DP) myeloid cell population,
Fig. 1 IL-12 induction of iNOS in TAM. a Quantitative RT-PCR
analysis of iNOS expression in tumors. Fine needle aspirates were ob-
tained from pre- (day 0) and post-therapy (days 1, 2, 3, and 7) tumors,
and the fold-change in iNOS as well as arginase mRNAs was quanti-
Wed. *The increases in iNOS expression on days 1–7 were signiWcant
compared to day 0 (P · 0.001), and day 2 iNOS expression was
signiWcantly higher than all other days (P · 0.0029). The changes in
arginase expression were not signiWcant. Error bars = SD, n = 5–8
mice per time point.  b Flow cytometric analysis of tumor-inWltrating
myeloid cell subsets. Single-cell suspensions prepared from post-
therapy day 2 tumors were analyzed for CD11b+ Gr1+ populations.
Control tumors displayed an essentially identical proWle (data not
shown). c Analysis of intratumoral myeloid cell subsets for iNOS.
The subsets identiWed in (b) were gated on and analyzed for membrane
F4/80 and intracellular iNOS in control and IL-12-treated mice. Typi-
cal staining proWles for the P1 and P2/P3 populations are shown (Both
P2 and P3 populations were negative for iNOS). P1 population could
be separated into F4/80 ¡ (P1a) and + (P1b) subsets with a portion of
the F4/80+ cells staining positive for iNOS. Isotype controls for F4/80,
iNOS, and other markers are shown in supplemental Figure 1. CD11b-
negative populations (including the tumor cells) did not express iNOS
(supplemental Figure 1).  d Kinetics of iNOS expression in TAM. Per-
cent of CD11bint Gr1lo F4/80+ TAM that were iNOS+ were quantiWed
on days 0 (pre-therapy), 2, and 7. *The diVerences between day 2 and
days 0 or 7 were signiWcant (P · 0.0029). Error bars = SD, n = 4 mice
per group.  e  Quantitative analysis of tumor-inWltrating leukocyte sub-
sets. T-regulatory cells (Treg, CD4+ CD25+ Foxp3+), T-helper cells
(TH, CD4+ Foxp3¡), CD8+ T-cells (CD3+ CD8+), NKT cells (CD3+
CD1d tetramer+), NK cells (CD45+ CD3¡ DX5+), dendritic cells
(DC, CD11c+ CD11blo Gr1¡ MHC Class II+), and P1/P2/P3 popula-
tions (as deWned above) in untreated tumors were quantiWed. The
diVerences between myeloid cell subsets (P1, P2, P3) and all other pop-
ulations were highly signiWcant (P · 0.0000002). Error bars = SD,
n = 5–9 mice per subset.f Induction of iNOS in wild-type vs IFN-KO
mice. Fold-changes in iNOS mRNA levels between day 0 and day 2
tumors were quantiWed by qRT-PCR in wild-type and IFN-KO mice.
Error bars = SD, n = 4–5 mice per group
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which includes neutrophils, macrophages, and myeloid-
derived suppressor cells (MDSC) [23]. To this end, tumor-
resident myeloid cell populations (Fig. 1b) were analyzed
for iNOS via intracellular staining (Fig. 1c). Among the
diVerent tumor-inWltrating DP myeloid subpopulations,
only a subset of the CD11bint, Gr1lo, and F4/80+ cells (P1b)
stained positively for iNOS whereas the CD11bint, Gr1lo,
F4/80¡ (P1a), the Gr1high, CD11bint (P2), and the Gr1high,
CD11bhigh (P3) populations did not (Fig. 1c). Similarly,
CD11c+ CD11blo Gr1¡ MHC Class II+ dendritic cells
(DC) failed to stain for iNOS (data not shown).
Treatment with IL-12 induced a rapid expansion of the
iNOS-expressing P1b subset but had no eVect on other
myeloid cell populations (Fig. 1c). Further characterization
of the iNOS-producing CD11bint, Gr1lo and F4/80+ P1b
subset revealed that these cells expressed low levels of
Ly6G, Ly6C, and MHCII and were negative for CCR3
(Supplemental Figure 1), a phenotype that is consistent
with that of a macrophage. The other myeloid subsets, i.e.,
P1a, P2, and P3 were not pursued further in this study as
they did not express iNOS before or after treatment. Quan-
titative monitoring of iNOS expression in CD11bint, Gr1lo,
and F4/80+ TAM revealed a threefold increase in the iNOS-
expressing subset on day 2 followed by a decline to pre-
therapy levels on day 7 consistent with the overall mRNA
pattern (Fig. 1d). Further analysis of tumor-inWltrating leu-
kocyte (TIL) populations revealed that the P1 population
constituted a signiWcant proportion of pre-treatment TIL
(Fig. 1e), supporting the notion that macrophage-produced
NO was a prominent component of post-IL-12 immunity.
Finally, IL-12-dependent induction of iNOS was strictly
dependent on IFN as treatment failed to induce iNOS in
IFN-knockout mice (Fig. 1f).
Inhibition of iNOS enhances IL-12-mediated tumor 
suppression in a CD8+ T-cell-dependent manner
The subsequent experiments were designed to directly
determine the role of macrophage-produced NO in IL-12-
mediated tumor suppression. To this end, we Wrst investi-
gated whether blocking of iNOS activity in IL-12-treated
mice via daily i.p injections of L-NAME could alter tumor
growth patterns. Data presented in Fig. 2a show that L-NAME
or IL-12 treatment alone induced transient suppression of
tumor growth compared to the control (untreated) group.
Concurrent administration of L-NAME with IL-12 micro-
spheres, on the other hand, resulted in a dramatic and
highly signiWcant enhancement of tumor kill. Although
cure was not achieved, tumors were completely arrested in
2 of 7 mice in the combined therapy group in comparison
with other groups in which tumors grew progressively.
We next examined the potential mechanism(s) underlying
the synergy between IL-12 and NO inhibition. L-NAME has
been shown to exert its steady-state anticancer eVects via
blocking of NO-driven angiogenic mechanisms [24, 25]. In
contrast, others have demonstrated that L-NAME can aug-
ment vaccine-induced antitumor CTL activity by blocking
the harmful eVects of NO on T-cell priming in a vaccine reg-
imen involving irradiated tumor cells and soluble IL-12 [13].
To determine whether the synergistic activity of L-NAME
was associated with its ability to block the detrimental eVects
of NO on T cells or involved a T-cell-independent mechanism,
intratumoral CD8+ T-cell mRNA levels and CD8+ T-cell
numbers were monitored in control and IL-12 + L-NAME
groups. The results revealed that inhibition of iNOS activity
during IL-12 therapy signiWcantly enhanced CD8+ T-cell
inWltration (Fig. 2b, c), whereas treatment with IL-12 or
L-NAME alone had no eVect on intratumoral CD8+ T-cell
numbers. To conWrm that the beneWcial eVect of L-NAME
was associated with enhanced CD8+ T-cell activity, in vivo
depletion of CD8+ T cells was performed prior to adminis-
tration of combination therapy. Data shown in Fig. 2d dem-
onstrate that tumor suppression was completely lost in the
absence of CD8+ T cells establishing the critical role of CTL
in L-NAME-dependent augmentation of tumor kill.
Enhanced CD8+ T-cell inWltration in L-NAME-treated 
mice is due to increased viability and proliferation 
of tumor-associated CD8+ Tem
We then investigated the mechanism underlying the rapid
increase in intratumoral CD8+ T-cell numbers in mice
receiving combination therapy. Previous studies had dem-
onstrated that IL-12 restored cytotoxic activity to tumor-
resident CD8+ Tem but that the cytotoxic activity was
short-lived as the cells apoptosed within 3–4 days of treat-
ment [17]. To determine whether inhibition of iNOS during
IL-12 therapy aVected the functional kinetics of tumor-resi-
dent CD8+ Tem, the cells were monitored for activation
and proliferation. Analysis of CD8+ Tem for CD43 and
CD69 expression revealed that treatment with IL-12 alone
or IL-12 + L-NAME resulted in equally eVective activation
(Fig. 3a). In contrast, post-activation biology of CD8+ Tem
was dramatically diVerent in IL-12-alone and IL-12 +
L-NAME groups. SpeciWcally, CD8+ Tem failed to prolif-
erate and apoptosed rapidly in the IL-12-alone group
whereas combination treatment enhanced viability and led
to robust cell division (Figs. 3b, c). These Wndings estab-
lished that post-L-NAME/IL-12 T-cell expansion was due
to the proliferation of pre-existing tumor-resident CD8+ Tem.
Finally, the link between the macrophage-iNOS axis and
CD8+ Tem apoptosis was examined in a study where the
eVect of macrophage depletion on post-therapy CD8+ Tem
survival and proliferation was evaluated. Administration of
clodrolip, a macrophage-depleting agent [20], prior to IL-12
treatment resulted in the elimination of the iNOS-expressing
Cancer Immunol Immunother
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TAM and a concurrent 2.5-fold increase in BrdU
incorporation by intratumoral CD8+ T cells further conWrming
the link between macrophage-produced iNOS and prema-
ture CD8+ T-cell apoptosis in IL-12-treated tumors
(Fig. 3d).
Discussion
The data presented here establish that the IL-12-IFN-
iNOS axis represents a major, therapy-induced, feedback
inhibitory mechanism that regulates IL-12-mediated cyto-
toxic T-cell response. The results also identify TAM as the
only detectable source of iNOS among tumor-inWltrating
myeloid cell populations. The induction of iNOS in treated
tumors is rapid and persists for at least 1 week, suggesting
that the CD8+ T-cell eVector window is tightly controlled
by NO.
Our Wndings shed further light on the controversial role
of macrophage-produced NO in TH1-targeted tumor ther-
apy and establish that the immune inhibitory function of
NO trumps its potential antitumor eVects. These data are
Fig. 2 EVect of combined therapy with IL-12 and L-NAME on CD8+
T-cell-mediated tumor kill. a Tumor growth patterns during treatment.
Mice-bearing subcutaneous Line-1 tumors (70–80 mm3) were treated
either with IL-12, L-NAME, or both. Control mice received blank
microspheres. Tumor volume was determined daily using the formula
a2 £ b/2, where a and b are the shortest and longest perpendicular
dimensions of the tumor, respectively. *The diVerences between the
IL-12 + L-NAME-treated group and control were signiWcant
(P · 0.0013 on days 1–10). The diVerences between the IL-12 +
L-NAME group and IL-12 alone or L-NAME alone groups were also
signiWcant between days 3 and 10 (P · 0.025). #,&The diVerences
between IL-12 alone and control groups were signiWcant between days
4 and 10 (P · 0.044) whereas the diVerences between L-NAME alone
and control groups were signiWcant only on days 9 and 10 (P · 0.039).
Error bars = SD, n = 5–8 mice per group. b Fold-change in intratu-
moral CD8 expression. Quantitative RT-PCR was employed to deter-
mine the relative levels of CD8 mRNA in pre- (day 0) and post-
treatment (day 2) tumors. The fold-changes shown are relative to the
control group. *The diVerences between the combined treatment group
and IL-12 or L-NAME-alone groups were signiWcant (P · 0.035).
Error bars = SD, n = 5–9 per group. c Intratumoral CD8+ T-cell
numbers. CD8+ T-cell numbers were quantiWed by Xow cytometric
analysis of day 2 tumors. *The diVerences between the combined
therapy group and other groups were signiWcant (P · 0.013). Error
bars = SD, n = 5–8 mice per group. d EVect of CD8+ T-cell depletion
on therapeutic eYcacy. Mice were injected with anti-CD8 or a control
isotype antibody 1 day prior to microsphere treatment and again on day
5 after treatment. Fold-changes in tumor volume between days 0 and
10 were determined. Error bars = SD, n = 5–8 mice/group
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also consistent with an earlier report, which showed that
tumor cytotoxicity of IL-12-activated macrophages does
not require iNOS activity [3]. One exception to these Wnd-
ings is our previous study that identiWed NO as a major
IL-12-induced antitumor eVector molecule in an intact
human tumor biopsy/SCID mouse xenograft model [4]. In
this model, the antitumor eVects of IL-12 were mediated
primarily by tumor-associated human CD4+ T cells via the
IFN-iNOS axis [4]. The seeming contradiction is likely
associated with the limitations of the human tumor/SCID
mouse xenograft model. In the immunologically intact
syngeneic murine tumor models, intratumoral administra-
tion of IL-12 results in rapid but transient restoration of
cytotoxic activity to pre-existing tumor-resident CD8+
T-eVector/memory (Tem) cells, which in turn mobilize
both the recruitment of NK cells [19] and the priming of a
secondary long-term CD8+ T-eVector cell response in the
TDLN [17, 21]. In contrast, neither of these eVector mecha-
nisms can occur in the xenograft model as (a) TDLN of
SCID do not contain naïve CD8+ T cells (human or mouse)
and (b) engrafted human tumors have few human NK cells
and murine NK cells do not respond to human IL-12 or
IFN. It is thus likely that in the absence of the NO-sensitive
primary eVectors, the normally obscure CD4+ T-cell-IFN-
iNOS eVector pathway becomes a prominent mechanism of
tumor kill.
Previous studies in our laboratory revealed that the
activation of pre-existing CD8+ Tem was transient and that
Fig. 3 EVect of L-NAME on post-therapy CD8+ Tem activity.
a CD8+ Tem activation. Expression of CD43 and CD69 on day 2
post-treatment CD8+ Tem is shown. *The diVerences between IL-12-
alone or IL-12 + L-NAME groups and control or L-NAME-alone were
signiWcant (P · 0.0025). Error bars = SD, n = 4–5 per group. b CD8+
Tem apoptosis. Day 2 post-treatment CD8+ Tem were stained with
Annexin V. IL-12-alone group was signiWcantly diVerent from all oth-
er groups (P · 0.021). Error bars = SD, n = 4–5 per group. c Post-
therapy CD8+ Tem proliferation. CD8+ Tem were stained for BrdU on
day 2. *The diVerences between the IL-12 + L-NAME group and the
other 3 groups were signiWcant (P · 0.025). Error bars = SD, n = 4–5
per group. d EVect of macrophage depletion on CD8+ Tem prolifera-
tion. The dot plots demonstrate that clodrolip depleted >80% of the
iNOS-producing macrophages found in the tumor (42,280 § 5,800
cells/g tumor vs. 9,200 § 3,200 cells/g tumor in control vs. clodrolip
groups, respectively, P = 0.0000013). The diVerences between the
clodrolip+ IL-12 group and the controls with respect to percent
proliferating CD8+ Tem were signiWcant (P · 0.014). Error
bars = SD, n = 4 per group
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these cells not only failed to proliferate but also succumbed
to apoptotic cell death within 3–4 days of IL-12 treatment
[17]. At the time, post-therapy CD8+ Tem death was inter-
preted as the result of activation-induced cell death. The
Wndings above, i.e., the demonstration that macrophage
depletion or inhibition of iNOS resulted in the abrogation of
CD8+ Tem apoptosis, establish that post-activation T-cell
death was due to the release of toxic metabolites from TAM.
Importantly, L-NAME-mediated NO-blockade allowed
rapid expansion of activated CD8+ Tem, ultimately result-
ing in a dramatic enhancement of tumor suppression.
Collectively, these data suggest that L-NAME may be criti-
cal to improve the reported transient antitumor eVects of
IL-12 in the clinic [26].
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